Business Context and Reporting Period
Company: Keros Therapeutics, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: November 4, 2021
Reporting Period: Single event date (November 4, 2021)
Business Context: The filing serves as a Regulation FD disclosure to update the corporate presentation used in meetings with investors and analysts. The updated presentation is attached as Exhibit 99.1.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The document is a procedural disclosure regarding the release of a corporate presentation.
Material Changes
No material financial changes or operational events are reported in this filing. The sole material action is the update and distribution of the company's corporate presentation.
Guidance, Outlook, and Risks
Management Commentary: The filing states that the information contained herein and in the accompanying exhibit is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934. Consequently, the information is not subject to the liabilities of that section and is not incorporated by reference into other filings unless expressly stated.
Guidance and Risks: The filing text does not provide specific guidance, outlook, risks, contingencies, or unusual items. These details, if any, would be contained within the attached Exhibit 99.1 (Corporate Presentation), which is not part of the provided text.
Investor Verification Checklist
- Review the attached Exhibit 99.1 (Corporate Presentation) for specific updates to the company's pipeline, financial outlook, or strategic direction.
- Verify that the presentation has been posted on the company's official investor relations website.
- Note that the content of the presentation is not legally "filed" with the SEC and carries different liability standards than formal financial reports.